Charles River Laboratories International, Inc. CRL
Set alert
At close · Nov 2
After hours · Nov 2, 6:51 PM ET
- YTD
- +69.71%
- 1 year
- +88.00%
- Open
- 368.42
- Prev close
- 359.41
- Mkt cap
- 16.16B
- Vol
- 1.62M
- Avg vol
- 1.03M
- EPS
- -4.80
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 337.38
- High
- 369.61
- Forward P/E
- 26.55
- Beta
- 1.34
- Short ratio
- 2.77
- Inst. own
- 122.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 301.91
- 200-d avg
- 221.78
- 1y target
- 318.87
5D chart
Signals (154)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:30 PM | 6 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 6 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 6 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 6 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 7 hours ago |
| MACD: Buy Signal | Nov 2, 3:00 PM | 7 hours ago |
| RSI: Oversold | Nov 2, 2:45 PM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 2:40 PM | 7 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 7 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 7 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 7 hours ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 8 hours ago |
| SMA: Bearish | Nov 2, 1:25 PM | 8 hours ago |
| SMA: Bullish | Nov 2, 1:20 PM | 8 hours ago |
| SMA: Bearish | Nov 2, 12:40 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 9 hours ago |
| MACD: Buy Signal | Nov 2, 12:10 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 12:05 PM | 10 hours ago |
| RSI: Oversold | Nov 2, 11:40 AM | 10 hours ago |
| RSI: Oversold | Nov 2, 11:15 AM | 10 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 11 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 11 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 12 hours ago |
| SMA: Bullish | Nov 2, 9:55 AM | 12 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 9:40 AM | 12 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 12 hours ago |
| SMA: Bullish | Oct 30, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:20 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:10 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:05 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:35 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
News
9 hours ago zacks.com
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
5 days ago zacks.com
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago seekingalpha.com
Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds…
-
6 days ago benzinga.com
Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen
This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the…
6 days ago businesswire.com
Charles River Leverages Virtual Control Groups in GLP Studies
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
6 days ago defenseworld.net
Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) Director James Foster sold 24,042 shares of the company's stock in a transaction dated Thursday, October 22nd. The shares…
6 days ago defenseworld.net
8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC
Evergreen Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE: CRL) in the third quarter, according to its most recent disclosure with the Securities…
1 week ago seekingalpha.com
Ariel Fund Q3 2026 Leaders And Laggards
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology…
-
1 week ago benzinga.com
Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs
Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
1 week ago businesswire.com
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of…
1 week ago benzinga.com
$1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market…
1 week ago benzinga.com
SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
2 weeks ago defenseworld.net
Charles River Laboratories International (NYSE:CRL) Share Price Crosses Above 200 Day Moving Average – Should You Sell?
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred…
2 weeks ago benzinga.com
Here’s How Much You Would Have Made Owning Charles River Stock In The Last 20 Years
Charles River (NYSE:CRL) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.15%. Currently, Charles River has a market…
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $340.
-
2 weeks ago benzinga.com
Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the…
2 weeks ago businesswire.com
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce…
3 weeks ago businesswire.com
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.
3 weeks ago zacks.com
PGNY or CRL: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for…
3 weeks ago zacks.com
Charles River Gains 75.8% in a Year: What's Driving the Rally?
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
-
3 weeks ago benzinga.com
Charles River Laboratories and Autolomous Launch Apollo Orchestrate To Digitize Laboratory Execution Through autoloMATE Integration
Partnership reinforces continued investment in digitization, automation, and client-facing transparencyCharles River Laboratories International, Inc. (NYSE:CRL) and Autolomous today announced the…
3 weeks ago businesswire.com
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new…
-
1 month ago benzinga.com
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market…
1 month ago defenseworld.net
Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Price Target of $290.00 According to Analysts
Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are…
-
1 month ago benzinga.com
Jefferies Maintains Buy on Charles River, Raises Price Target to $340
Jefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.
1 month ago marketbeat.com
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets…
-
1 month ago benzinga.com
Deutsche Bank Maintains Buy on Charles River, Raises Price Target to $320
Deutsche Bank analyst Justin Bowers maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $320.
-
1 month ago benzinga.com
TD Cowen Maintains Buy on Charles River, Raises Price Target to $325
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $300 to $325.
-
1 month ago benzinga.com
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $330
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $320 to $330.
-
1 month ago benzinga.com
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $322
RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $282 to $322.
-
1 month ago benzinga.com
Barclays Maintains Overweight on Charles River, Raises Price Target to $330
Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $300 to $330.
-
1 month ago benzinga.com
Mizuho Maintains Neutral on Charles River, Raises Price Target to $295
Mizuho analyst Ann Hynes maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $264 to $295.
-
1 month ago benzinga.com
Baird Maintains Outperform on Charles River, Raises Price Target to $334
Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.
1 month ago seekingalpha.com
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
1 month ago benzinga.com
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
1 month ago benzinga.com
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Nasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
-
1 month ago benzinga.com
Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%
Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term…
1 month ago businesswire.com
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.
1 month ago defenseworld.net
Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)
Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business?…
1 month ago zacks.com
PGNY vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the…
1 month ago businesswire.com
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release…
-
1 month ago benzinga.com
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.57% on an annualized basis producing an average annual return of 15.86%. Currently, Charles River has a market…
-
1 month ago benzinga.com
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320
Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.
2 months ago benzinga.com
Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market…
-
2 months ago benzinga.com
Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine
Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International,…
-
2 months ago benzinga.com
If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market…
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Charles River, Raises Price Target to $300
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $235 to $300.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $300
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $260 to $300.
2 months ago benzinga.com
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $282
RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $215 to $282.